 Sharon Pine
Concepts (308)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Neoplasms | 32 | 2025 | 2567 | 3.010 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 10 | 2025 | 1127 | 1.540 |
Why?
| | Biomarkers, Tumor | 12 | 2025 | 1258 | 1.170 |
Why?
| | Amyloid Precursor Protein Secretases | 3 | 2018 | 79 | 1.170 |
Why?
| | SOX9 Transcription Factor | 3 | 2023 | 26 | 1.130 |
Why?
| | Leukemia, Megakaryoblastic, Acute | 4 | 2007 | 10 | 0.830 |
Why?
| | Receptor, Notch1 | 2 | 2014 | 65 | 0.810 |
Why?
| | GATA1 Transcription Factor | 4 | 2007 | 18 | 0.780 |
Why?
| | DNA, Neoplasm | 4 | 2010 | 158 | 0.730 |
Why?
| | STAT Transcription Factors | 1 | 2021 | 16 | 0.730 |
Why?
| | Janus Kinases | 1 | 2021 | 15 | 0.730 |
Why?
| | Paclitaxel | 2 | 2022 | 237 | 0.670 |
Why?
| | Signal Transduction | 9 | 2021 | 5169 | 0.640 |
Why?
| | Carcinoma, Squamous Cell | 4 | 2025 | 645 | 0.630 |
Why?
| | Neoplastic Stem Cells | 3 | 2013 | 408 | 0.580 |
Why?
| | Inflammation | 4 | 2022 | 2902 | 0.570 |
Why?
| | Protease Inhibitors | 1 | 2018 | 105 | 0.550 |
Why?
| | Benzodiazepinones | 1 | 2017 | 18 | 0.550 |
Why?
| | Neoplasms | 4 | 2025 | 2747 | 0.540 |
Why?
| | Gene Expression Regulation, Neoplastic | 9 | 2025 | 1435 | 0.530 |
Why?
| | Cell Line, Tumor | 13 | 2023 | 3495 | 0.510 |
Why?
| | Antineoplastic Agents | 7 | 2023 | 2169 | 0.510 |
Why?
| | Down Syndrome | 4 | 2007 | 506 | 0.510 |
Why?
| | F-Box Proteins | 1 | 2016 | 21 | 0.500 |
Why?
| | Antineoplastic Agents, Phytogenic | 1 | 2017 | 192 | 0.490 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 3 | 2005 | 289 | 0.490 |
Why?
| | Proteasome Endopeptidase Complex | 1 | 2016 | 161 | 0.460 |
Why?
| | Drug Resistance, Neoplasm | 6 | 2021 | 833 | 0.460 |
Why?
| | Polymerase Chain Reaction | 5 | 2010 | 1056 | 0.450 |
Why?
| | Ubiquitin-Protein Ligases | 1 | 2016 | 175 | 0.450 |
Why?
| | Interleukin-8 | 3 | 2014 | 273 | 0.450 |
Why?
| | Neoplasms, Basal Cell | 1 | 2013 | 3 | 0.420 |
Why?
| | Chromosome Segregation | 1 | 2013 | 47 | 0.410 |
Why?
| | DNA Damage | 1 | 2016 | 429 | 0.410 |
Why?
| | DNA | 2 | 2022 | 1444 | 0.370 |
Why?
| | Cell Cycle Proteins | 1 | 2016 | 632 | 0.370 |
Why?
| | Interleukin-6 | 3 | 2019 | 792 | 0.370 |
Why?
| | C-Reactive Protein | 2 | 2011 | 424 | 0.360 |
Why?
| | Adenocarcinoma | 3 | 2017 | 896 | 0.350 |
Why?
| | Mannose-Binding Lectin | 2 | 2009 | 21 | 0.350 |
Why?
| | Proto-Oncogene Proteins c-mdm2 | 2 | 2012 | 66 | 0.330 |
Why?
| | Oncogene Proteins, Fusion | 3 | 2017 | 204 | 0.330 |
Why?
| | Humans | 52 | 2025 | 141754 | 0.330 |
Why?
| | Smoking | 6 | 2024 | 1603 | 0.330 |
Why?
| | Case-Control Studies | 14 | 2024 | 3597 | 0.320 |
Why?
| | Cell Transformation, Neoplastic | 2 | 2021 | 334 | 0.320 |
Why?
| | Mutation | 9 | 2023 | 4015 | 0.310 |
Why?
| | Polymorphism, Single Nucleotide | 6 | 2019 | 2135 | 0.300 |
Why?
| | Mice | 12 | 2023 | 18109 | 0.290 |
Why?
| | Polymorphism, Genetic | 2 | 2009 | 625 | 0.280 |
Why?
| | Cytokines | 1 | 2015 | 2100 | 0.270 |
Why?
| | Inflammation Mediators | 2 | 2021 | 519 | 0.270 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 3 | 2023 | 263 | 0.270 |
Why?
| | Lymphoma, AIDS-Related | 1 | 2007 | 14 | 0.260 |
Why?
| | Molecular Targeted Therapy | 2 | 2021 | 420 | 0.260 |
Why?
| | Lymphoproliferative Disorders | 1 | 2007 | 60 | 0.250 |
Why?
| | Leukemia | 2 | 2007 | 244 | 0.250 |
Why?
| | Animals | 14 | 2023 | 37749 | 0.250 |
Why?
| | Lymphoma, Non-Hodgkin | 1 | 2007 | 123 | 0.240 |
Why?
| | Nuclear Weapons | 1 | 2025 | 7 | 0.240 |
Why?
| | Cell Proliferation | 7 | 2021 | 2506 | 0.230 |
Why?
| | Neoplasms, Radiation-Induced | 1 | 2025 | 103 | 0.220 |
Why?
| | Breast Neoplasms | 2 | 2013 | 2257 | 0.210 |
Why?
| | Female | 31 | 2025 | 75943 | 0.210 |
Why?
| | Carboplatin | 2 | 2022 | 146 | 0.210 |
Why?
| | Smokers | 1 | 2024 | 144 | 0.200 |
Why?
| | Tumor Microenvironment | 3 | 2023 | 703 | 0.200 |
Why?
| | Genes, ras | 1 | 2023 | 95 | 0.200 |
Why?
| | Aged | 19 | 2024 | 24746 | 0.200 |
Why?
| | Alternative Splicing | 1 | 2025 | 232 | 0.190 |
Why?
| | Central Nervous System Neoplasms | 1 | 2005 | 169 | 0.190 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 1 | 2022 | 97 | 0.180 |
Why?
| | Base Sequence | 4 | 2014 | 2180 | 0.180 |
Why?
| | Intracellular Signaling Peptides and Proteins | 2 | 2022 | 467 | 0.180 |
Why?
| | Epithelial-Mesenchymal Transition | 2 | 2014 | 213 | 0.180 |
Why?
| | Mechanistic Target of Rapamycin Complex 1 | 1 | 2022 | 132 | 0.180 |
Why?
| | Pyrazines | 1 | 2022 | 88 | 0.180 |
Why?
| | Cell Movement | 3 | 2020 | 990 | 0.180 |
Why?
| | Ribosome Subunits, Large, Eukaryotic | 1 | 2021 | 3 | 0.180 |
Why?
| | Superoxide Dismutase-1 | 1 | 2021 | 12 | 0.180 |
Why?
| | Organelle Biogenesis | 1 | 2021 | 15 | 0.180 |
Why?
| | Immunity, Innate | 1 | 2007 | 852 | 0.170 |
Why?
| | Triazoles | 1 | 2022 | 162 | 0.170 |
Why?
| | Cytokinesis | 1 | 2021 | 50 | 0.170 |
Why?
| | Middle Aged | 18 | 2024 | 34647 | 0.170 |
Why?
| | Adenocarcinoma, Mucinous | 1 | 2021 | 76 | 0.170 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2022 | 368 | 0.160 |
Why?
| | Receptors, Kisspeptin-1 | 1 | 2020 | 2 | 0.160 |
Why?
| | Prognosis | 7 | 2024 | 4080 | 0.160 |
Why?
| | Male | 25 | 2025 | 70179 | 0.160 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2022 | 444 | 0.160 |
Why?
| | Receptor-Like Protein Tyrosine Phosphatases, Class 2 | 1 | 2019 | 10 | 0.160 |
Why?
| | Molecular Sequence Data | 3 | 2014 | 2929 | 0.160 |
Why?
| | Janus Kinase 2 | 1 | 2019 | 32 | 0.160 |
Why?
| | Disease Susceptibility | 1 | 2021 | 353 | 0.160 |
Why?
| | Molecular Chaperones | 1 | 2021 | 198 | 0.150 |
Why?
| | Mice, Inbred NOD | 2 | 2020 | 600 | 0.150 |
Why?
| | Cellular Senescence | 2 | 2013 | 206 | 0.150 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2022 | 429 | 0.150 |
Why?
| | Cellular Reprogramming | 1 | 2020 | 99 | 0.150 |
Why?
| | Biomarkers | 2 | 2021 | 4190 | 0.150 |
Why?
| | Neoplasm, Residual | 3 | 2005 | 132 | 0.150 |
Why?
| | Acrylamides | 1 | 2019 | 67 | 0.150 |
Why?
| | Combined Modality Therapy | 1 | 2021 | 1249 | 0.150 |
Why?
| | Nanotechnology | 1 | 2019 | 124 | 0.140 |
Why?
| | Aniline Compounds | 1 | 2019 | 120 | 0.140 |
Why?
| | Proteolysis | 2 | 2016 | 175 | 0.140 |
Why?
| | Carcinogenesis | 1 | 2020 | 215 | 0.140 |
Why?
| | Quinolines | 1 | 2019 | 172 | 0.140 |
Why?
| | Risk Factors | 8 | 2015 | 10482 | 0.140 |
Why?
| | Receptors, Notch | 1 | 2018 | 87 | 0.140 |
Why?
| | Quinazolines | 1 | 2019 | 260 | 0.140 |
Why?
| | Transcriptome | 1 | 2024 | 1014 | 0.140 |
Why?
| | Transfection | 2 | 2017 | 943 | 0.140 |
Why?
| | Lung | 4 | 2022 | 4137 | 0.130 |
Why?
| | Disease Management | 1 | 2021 | 633 | 0.130 |
Why?
| | Tumor Suppressor Protein p53 | 2 | 2013 | 529 | 0.130 |
Why?
| | Triple Negative Breast Neoplasms | 1 | 2020 | 200 | 0.130 |
Why?
| | CD24 Antigen | 2 | 2013 | 19 | 0.130 |
Why?
| | Cancer Survivors | 1 | 2022 | 302 | 0.130 |
Why?
| | F-Box-WD Repeat-Containing Protein 7 | 1 | 2016 | 6 | 0.130 |
Why?
| | Neoplasm Invasiveness | 2 | 2020 | 510 | 0.130 |
Why?
| | Hyaluronan Receptors | 2 | 2013 | 103 | 0.120 |
Why?
| | Glycogen Synthase Kinase 3 beta | 1 | 2016 | 73 | 0.120 |
Why?
| | Ubiquitination | 1 | 2016 | 107 | 0.120 |
Why?
| | Proportional Hazards Models | 2 | 2011 | 1268 | 0.120 |
Why?
| | Coculture Techniques | 2 | 2013 | 245 | 0.120 |
Why?
| | Protein Interaction Domains and Motifs | 1 | 2016 | 150 | 0.120 |
Why?
| | Proto-Oncogene Proteins B-raf | 1 | 2017 | 223 | 0.110 |
Why?
| | Cell Division | 3 | 2013 | 798 | 0.110 |
Why?
| | Receptors, Interleukin-8B | 1 | 2014 | 26 | 0.110 |
Why?
| | Protein Kinase Inhibitors | 2 | 2019 | 919 | 0.110 |
Why?
| | Cell Death | 1 | 2016 | 387 | 0.110 |
Why?
| | Protein Isoforms | 2 | 2013 | 398 | 0.110 |
Why?
| | Computational Biology | 1 | 2019 | 664 | 0.110 |
Why?
| | Patient Selection | 1 | 2018 | 688 | 0.110 |
Why?
| | Tumor Cells, Cultured | 2 | 2021 | 962 | 0.110 |
Why?
| | Gene Expression Profiling | 4 | 2025 | 1771 | 0.110 |
Why?
| | Software | 1 | 2019 | 678 | 0.110 |
Why?
| | 3' Untranslated Regions | 1 | 2014 | 149 | 0.110 |
Why?
| | Disease Progression | 1 | 2021 | 2800 | 0.100 |
Why?
| | Energy Metabolism | 1 | 2020 | 932 | 0.100 |
Why?
| | Ultraviolet Rays | 1 | 2016 | 401 | 0.100 |
Why?
| | Colorectal Neoplasms | 1 | 2021 | 805 | 0.100 |
Why?
| | Platinum Compounds | 1 | 2013 | 11 | 0.100 |
Why?
| | Genes, T-Cell Receptor | 2 | 2003 | 9 | 0.100 |
Why?
| | Dipeptides | 1 | 2013 | 54 | 0.100 |
Why?
| | Core Binding Factor Alpha 2 Subunit | 2 | 2003 | 29 | 0.100 |
Why?
| | Research Design | 2 | 2011 | 1146 | 0.100 |
Why?
| | Immunoglobulin Heavy Chains | 2 | 2003 | 85 | 0.100 |
Why?
| | Models, Biological | 2 | 2019 | 1828 | 0.100 |
Why?
| | Alleles | 3 | 2014 | 891 | 0.090 |
Why?
| | Survival Analysis | 2 | 2013 | 1320 | 0.090 |
Why?
| | Gene Expression Regulation | 1 | 2021 | 2608 | 0.090 |
Why?
| | Stromal Cells | 1 | 2012 | 117 | 0.090 |
Why?
| | Gap Junctions | 1 | 2012 | 63 | 0.090 |
Why?
| | Genotype | 4 | 2014 | 1866 | 0.090 |
Why?
| | Phosphorylation | 1 | 2016 | 1774 | 0.090 |
Why?
| | HIV Infections | 1 | 2007 | 3022 | 0.090 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2013 | 210 | 0.090 |
Why?
| | Risk Assessment | 3 | 2011 | 3508 | 0.090 |
Why?
| | National Cancer Institute (U.S.) | 1 | 2011 | 48 | 0.090 |
Why?
| | Bone Marrow Cells | 1 | 2012 | 327 | 0.090 |
Why?
| | Japan | 2 | 2025 | 133 | 0.090 |
Why?
| | Cell Communication | 1 | 2012 | 318 | 0.080 |
Why?
| | ROC Curve | 2 | 2024 | 590 | 0.080 |
Why?
| | Adult | 8 | 2020 | 39391 | 0.080 |
Why?
| | Protein Binding | 1 | 2016 | 2242 | 0.080 |
Why?
| | AC133 Antigen | 1 | 2010 | 21 | 0.080 |
Why?
| | Melanoma | 1 | 2017 | 792 | 0.080 |
Why?
| | Bromodeoxyuridine | 1 | 2010 | 80 | 0.080 |
Why?
| | Phenotype | 3 | 2013 | 3177 | 0.080 |
Why?
| | Biopsy | 2 | 2017 | 1083 | 0.080 |
Why?
| | Logistic Models | 2 | 2011 | 2092 | 0.070 |
Why?
| | Exons | 2 | 2008 | 353 | 0.070 |
Why?
| | Infant | 3 | 2007 | 9843 | 0.070 |
Why?
| | DNA Replication | 1 | 2010 | 240 | 0.070 |
Why?
| | Genetic Predisposition to Disease | 4 | 2012 | 2375 | 0.070 |
Why?
| | Cell Differentiation | 2 | 2008 | 2006 | 0.070 |
Why?
| | Glycoproteins | 1 | 2010 | 358 | 0.070 |
Why?
| | Polymorphism, Single-Stranded Conformational | 1 | 2007 | 25 | 0.070 |
Why?
| | Baltimore | 1 | 2007 | 68 | 0.070 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2013 | 918 | 0.070 |
Why?
| | Smoking Cessation | 1 | 2011 | 440 | 0.070 |
Why?
| | Sequence Homology, Nucleic Acid | 1 | 2007 | 156 | 0.070 |
Why?
| | Tobacco Smoke Pollution | 1 | 2009 | 256 | 0.060 |
Why?
| | Prospective Studies | 2 | 2011 | 7777 | 0.060 |
Why?
| | Linkage Disequilibrium | 1 | 2007 | 255 | 0.060 |
Why?
| | Antigens, CD | 1 | 2010 | 545 | 0.060 |
Why?
| | Autophagy | 2 | 2023 | 287 | 0.060 |
Why?
| | DNA Primers | 2 | 2008 | 510 | 0.060 |
Why?
| | Infant, Newborn | 3 | 2007 | 6289 | 0.060 |
Why?
| | ErbB Receptors | 2 | 2019 | 610 | 0.060 |
Why?
| | Neoplasm Staging | 3 | 2017 | 1401 | 0.060 |
Why?
| | Superoxide Dismutase | 1 | 2008 | 352 | 0.060 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2007 | 311 | 0.060 |
Why?
| | Haplotypes | 1 | 2007 | 499 | 0.060 |
Why?
| | Disease-Free Survival | 1 | 2007 | 718 | 0.060 |
Why?
| | Predictive Value of Tests | 1 | 2011 | 2075 | 0.060 |
Why?
| | Chromosomes, Human, Pair 21 | 1 | 2005 | 42 | 0.060 |
Why?
| | Gene Knockdown Techniques | 2 | 2021 | 333 | 0.060 |
Why?
| | Preservation, Biological | 1 | 2005 | 8 | 0.060 |
Why?
| | United States | 3 | 2020 | 15310 | 0.060 |
Why?
| | Remission Induction | 1 | 2005 | 309 | 0.060 |
Why?
| | Liquid Biopsy | 1 | 2024 | 13 | 0.060 |
Why?
| | Cloning, Molecular | 1 | 2005 | 533 | 0.050 |
Why?
| | History, 21st Century | 1 | 2025 | 220 | 0.050 |
Why?
| | Tobacco Smoking | 1 | 2024 | 25 | 0.050 |
Why?
| | MicroRNAs | 3 | 2019 | 692 | 0.050 |
Why?
| | History, 20th Century | 1 | 2025 | 330 | 0.050 |
Why?
| | Mice, Knockout | 2 | 2021 | 3071 | 0.050 |
Why?
| | Peptides | 1 | 2010 | 979 | 0.050 |
Why?
| | Chronology as Topic | 1 | 2003 | 2 | 0.050 |
Why?
| | Chromosome Breakage | 1 | 2003 | 23 | 0.050 |
Why?
| | Reproducibility of Results | 2 | 2019 | 3356 | 0.050 |
Why?
| | Gene Expression | 1 | 2008 | 1492 | 0.050 |
Why?
| | Mitogen-Activated Protein Kinase Kinases | 1 | 2023 | 132 | 0.050 |
Why?
| | Clone Cells | 1 | 2003 | 267 | 0.050 |
Why?
| | Mucins | 1 | 2022 | 75 | 0.050 |
Why?
| | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2003 | 79 | 0.050 |
Why?
| | Promoter Regions, Genetic | 1 | 2006 | 1243 | 0.040 |
Why?
| | Immunophenotyping | 1 | 2003 | 329 | 0.040 |
Why?
| | Apoptosis | 2 | 2021 | 2576 | 0.040 |
Why?
| | Cell Nucleolus | 1 | 2021 | 17 | 0.040 |
Why?
| | Child | 4 | 2009 | 22414 | 0.040 |
Why?
| | Adenosine | 1 | 2022 | 253 | 0.040 |
Why?
| | RNA Processing, Post-Transcriptional | 1 | 2021 | 91 | 0.040 |
Why?
| | Time Factors | 1 | 2011 | 6966 | 0.040 |
Why?
| | Mutagenesis, Site-Directed | 1 | 2021 | 377 | 0.040 |
Why?
| | Aftercare | 1 | 2022 | 218 | 0.040 |
Why?
| | Glutaminase | 1 | 2020 | 11 | 0.040 |
Why?
| | Down-Regulation | 1 | 2022 | 641 | 0.040 |
Why?
| | Precision Medicine | 1 | 2024 | 434 | 0.040 |
Why?
| | Fibrosis | 1 | 2022 | 542 | 0.040 |
Why?
| | RNA Precursors | 1 | 2021 | 156 | 0.040 |
Why?
| | Africa, Western | 1 | 2019 | 21 | 0.040 |
Why?
| | A549 Cells | 1 | 2019 | 74 | 0.040 |
Why?
| | Mice, Nude | 1 | 2021 | 691 | 0.040 |
Why?
| | Tumor Stem Cell Assay | 1 | 2019 | 34 | 0.040 |
Why?
| | Glutamine | 1 | 2020 | 107 | 0.040 |
Why?
| | Recurrence | 1 | 2003 | 1111 | 0.040 |
Why?
| | Exome | 1 | 2020 | 238 | 0.040 |
Why?
| | Nucleotides | 1 | 2020 | 127 | 0.040 |
Why?
| | Child, Preschool | 2 | 2005 | 11512 | 0.040 |
Why?
| | Mice, SCID | 1 | 2020 | 367 | 0.040 |
Why?
| | Killer Cells, Natural | 1 | 2022 | 471 | 0.040 |
Why?
| | Tumor Burden | 1 | 2020 | 312 | 0.040 |
Why?
| | DNA Mutational Analysis | 1 | 2019 | 398 | 0.040 |
Why?
| | Incidence | 2 | 2019 | 2806 | 0.040 |
Why?
| | Proto-Oncogene Proteins c-myc | 1 | 2020 | 163 | 0.040 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2021 | 907 | 0.040 |
Why?
| | Survivors | 1 | 2022 | 504 | 0.040 |
Why?
| | STAT3 Transcription Factor | 1 | 2019 | 212 | 0.030 |
Why?
| | Cell Nucleus | 1 | 2021 | 609 | 0.030 |
Why?
| | Immunotherapy | 1 | 2022 | 646 | 0.030 |
Why?
| | B-Lymphocytes | 1 | 2003 | 859 | 0.030 |
Why?
| | Genetic Therapy | 1 | 2019 | 315 | 0.030 |
Why?
| | DNA-Binding Proteins | 1 | 2005 | 1485 | 0.030 |
Why?
| | Risk | 1 | 2019 | 907 | 0.030 |
Why?
| | Young Adult | 3 | 2020 | 13749 | 0.030 |
Why?
| | Transcription Factors | 1 | 2005 | 1712 | 0.030 |
Why?
| | Health Status Disparities | 1 | 2019 | 298 | 0.030 |
Why?
| | Positron Emission Tomography Computed Tomography | 1 | 2017 | 110 | 0.030 |
Why?
| | Follow-Up Studies | 2 | 2019 | 5212 | 0.030 |
Why?
| | Pyrimidines | 1 | 2019 | 512 | 0.030 |
Why?
| | Indoles | 1 | 2019 | 478 | 0.030 |
Why?
| | MAP Kinase Signaling System | 1 | 2017 | 326 | 0.030 |
Why?
| | Neoplasm Metastasis | 1 | 2017 | 676 | 0.030 |
Why?
| | Survival Rate | 1 | 2019 | 1972 | 0.030 |
Why?
| | Leupeptins | 1 | 2013 | 12 | 0.030 |
Why?
| | Cell Survival | 1 | 2017 | 1134 | 0.030 |
Why?
| | Macrolides | 1 | 2013 | 68 | 0.030 |
Why?
| | Transduction, Genetic | 1 | 2013 | 136 | 0.020 |
Why?
| | Octamer Transcription Factor-3 | 1 | 2012 | 18 | 0.020 |
Why?
| | Ligands | 1 | 2014 | 667 | 0.020 |
Why?
| | Binding Sites | 1 | 2014 | 1316 | 0.020 |
Why?
| | Neoplasm Proteins | 1 | 2013 | 434 | 0.020 |
Why?
| | Disease Models, Animal | 1 | 2021 | 4421 | 0.020 |
Why?
| | Cohort Studies | 2 | 2012 | 5815 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2021 | 5909 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2022 | 5697 | 0.020 |
Why?
| | Recombinant Proteins | 1 | 2013 | 1363 | 0.020 |
Why?
| | Early Detection of Cancer | 1 | 2014 | 444 | 0.020 |
Why?
| | Genetic Variation | 1 | 2014 | 1000 | 0.020 |
Why?
| | Confidence Intervals | 1 | 2010 | 329 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2024 | 11181 | 0.020 |
Why?
| | Age Distribution | 1 | 2010 | 397 | 0.020 |
Why?
| | Sex Distribution | 1 | 2010 | 381 | 0.020 |
Why?
| | Small Cell Lung Carcinoma | 1 | 2010 | 116 | 0.020 |
Why?
| | Reference Values | 1 | 2010 | 807 | 0.020 |
Why?
| | Enzyme Stability | 1 | 2008 | 71 | 0.020 |
Why?
| | Adolescent | 2 | 2009 | 22130 | 0.020 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2014 | 1078 | 0.020 |
Why?
| | Homozygote | 1 | 2008 | 201 | 0.020 |
Why?
| | Linear Models | 1 | 2010 | 858 | 0.020 |
Why?
| | Odds Ratio | 1 | 2010 | 1057 | 0.020 |
Why?
| | Amino Acid Substitution | 1 | 2008 | 310 | 0.020 |
Why?
| | Colonic Neoplasms | 1 | 2009 | 246 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2019 | 7923 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2008 | 987 | 0.020 |
Why?
| | Cells, Cultured | 1 | 2013 | 4212 | 0.010 |
Why?
| | Erythroid-Specific DNA-Binding Factors | 1 | 2005 | 15 | 0.010 |
Why?
| | Comorbidity | 1 | 2010 | 1664 | 0.010 |
Why?
| | Environmental Exposure | 1 | 2009 | 585 | 0.010 |
Why?
| | Aneuploidy | 1 | 2005 | 89 | 0.010 |
Why?
| | Genome-Wide Association Study | 1 | 2010 | 1406 | 0.010 |
Why?
| | Retrospective Studies | 1 | 2014 | 16374 | 0.010 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2005 | 1793 | 0.010 |
Why?
|
|
Pine's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|